Literature DB >> 23458155

Epidemiological features of amyotrophic lateral sclerosis in a large clinic-based African American population.

Mohamed Kazamel1, Gary Cutter, Gwendolyn Claussen, Mohammad Alsharabati, Shin J Oh, Liang Lu, Peter H King.   

Abstract

Our objective was to identify the main clinical and epidemiological features of ALS in a large cohort of African American (AA) patients and compare them to Caucasian (CA) patients in a clinic-based population. We retrospectively identified 207 patients who were diagnosed with ALS based on the revised El Escorial criteria (60 AA and 147 CA subjects). Patients were seen in the Neuromuscular Division at the University Medical Center. We compared epidemiological and clinical features of these two groups, focusing on age of onset and diagnosis, clinical presentation and survival. Results showed that AA patients had a significantly younger age of disease onset (55 years vs. 61 years for CA, p = 0.011) and were diagnosed at an earlier age (56 years vs. 62 years, p = 0.012). In younger ALS patients (< 45 years of age), there was a significant difference in gender frequency, with females predominating in the AA population and males in the CA population (p = 0.025). In a multivariable Cox proportional hazard model, survival rates were not different between the groups. In both groups, survival significantly increased with younger age. In conclusion, AA patients presented at an earlier age, but there was no difference in survival compared to CA patients. A gender reversal occurred in younger ALS patients, with AA patients more likely to be female and CA patients more likely to be male.

Entities:  

Mesh:

Year:  2013        PMID: 23458155      PMCID: PMC3732496          DOI: 10.3109/21678421.2013.770030

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  15 in total

Review 1.  Young-onset amyotrophic lateral sclerosis: historical and other observations.

Authors:  Martin R Turner; Jessica Barnwell; Ammar Al-Chalabi; Andrew Eisen
Journal:  Brain       Date:  2012-06-01       Impact factor: 13.501

Review 2.  Ethnic variation in the incidence of ALS: a systematic review.

Authors:  Simon Cronin; Orla Hardiman; Bryan J Traynor
Journal:  Neurology       Date:  2007-03-27       Impact factor: 9.910

3.  Predictors of emergent feeding tubes and tracheostomies in amyotrophic lateral sclerosis (ALS).

Authors:  Amy Y Tsou; Jason Karlawish; Leo McCluskey; Sharon X Xie; Judith A Long
Journal:  Amyotroph Lateral Scler       Date:  2012-05

4.  Motor neurone disease in the tropics: findings from Sudan.

Authors:  M N Abdulla; T E Sokrab; A el Tahir; H E Siddig; M E Ali
Journal:  East Afr Med J       Date:  1997-01

5.  The prognosis of motor neuron disease in Nigerian africans. A prospective study of 92 patients.

Authors:  B O Osuntokun; A O Adeuja; O Bademosi
Journal:  Brain       Date:  1974-06       Impact factor: 13.501

6.  Multiple sclerosis and amyotrophic lateral sclerosis in Mississippi.

Authors:  A E Breland; R D Currier
Journal:  Neurology       Date:  1967-10       Impact factor: 9.910

7.  Temporal and geographic variation in United States motor neuron disease mortality, 1969-1998.

Authors:  Curtis W Noonan; Mary C White; David Thurman; Lee-Yang Wong
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

8.  Natural history of young-adult amyotrophic lateral sclerosis.

Authors:  M Sabatelli; F Madia; A Conte; M Luigetti; M Zollino; I Mancuso; M Lo Monaco; G Lippi; P Tonali
Journal:  Neurology       Date:  2008-07-02       Impact factor: 9.910

9.  Prognosis of amyotrophic lateral sclerosis and the effect of referral selection.

Authors:  J R Lee; J F Annegers; S H Appel
Journal:  J Neurol Sci       Date:  1995-10       Impact factor: 3.181

10.  Reduced frequency of ALS in an ethnically mixed population: a population-based mortality study.

Authors:  T Zaldivar; J Gutierrez; G Lara; M Carbonara; G Logroscino; O Hardiman
Journal:  Neurology       Date:  2009-05-12       Impact factor: 9.910

View more
  12 in total

Review 1.  Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin.

Authors:  Benoît Marin; Giancarlo Logroscino; Farid Boumédiene; Anaïs Labrunie; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Pierre Marie Preux; Ettore Beghi
Journal:  Eur J Epidemiol       Date:  2015-10-12       Impact factor: 8.082

2.  Effects of demographic factors on survival time after a diagnosis of amyotrophic lateral sclerosis.

Authors:  Heather Jordan; Jerald Fagliano; Lindsay Rechtman; Daniel Lefkowitz; Wendy Kaye
Journal:  Neuroepidemiology       Date:  2015-03-17       Impact factor: 3.282

3.  Racial differences in motor neuron disease.

Authors:  Betul Gundogdu; Tawfiq Al-Lahham; Fred Kadlubar; Horace Spencer; Stacy A Rudnicki
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2013-09-25       Impact factor: 4.092

4.  Muscle microRNA signatures as biomarkers of disease progression in amyotrophic lateral sclerosis.

Authors:  Ying Si; Xianqin Cui; David K Crossman; Jiaying Hao; Mohamed Kazamel; Yuri Kwon; Peter H King
Journal:  Neurobiol Dis       Date:  2018-02-24       Impact factor: 5.996

5.  The vitamin D activator CYP27B1 is upregulated in muscle fibers in denervating disease and can track progression in amyotrophic lateral sclerosis.

Authors:  Ying Si; Mohamed Kazamel; Yuri Kwon; Ikjae Lee; Tina Anderson; Siyu Zhou; Marcas Bamman; Derek Wiggins; Thaddaeus Kwan; Peter H King
Journal:  J Steroid Biochem Mol Biol       Date:  2020-03-03       Impact factor: 4.292

6.  Fat mass loss correlates with faster disease progression in amyotrophic lateral sclerosis patients: Exploring the utility of dual-energy x-ray absorptiometry in a prospective study.

Authors:  Ikjae Lee; Mohamed Kazamel; Tarrant McPherson; Jeremy McAdam; Marcas Bamman; Amy Amara; Daniel L Smith; Peter H King
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

7.  Epidemiology and surveillance of amyotrophic lateral sclerosis in two large metropolitan areas in California.

Authors:  Jhaqueline Valle; Eric Roberts; Susan Paulukonis; Natalie Collins; Paul English; Wendy Kaye
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2015-03-30       Impact factor: 4.092

8.  FGF23, a novel muscle biomarker detected in the early stages of ALS.

Authors:  Ying Si; Mohamed Kazamel; Michael Benatar; Joanne Wuu; Yuri Kwon; Thaddaeus Kwan; Nan Jiang; Dominik Kentrup; Christian Faul; Lyndsy Alesce; Peter H King
Journal:  Sci Rep       Date:  2021-06-08       Impact factor: 4.379

9.  Racial and ethnic differences among amyotrophic lateral sclerosis cases in the United States.

Authors:  Lindsay Rechtman; Heather Jordan; Laurie Wagner; D Kevin Horton; Wendy Kaye
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-12-08       Impact factor: 4.092

10.  Smads as muscle biomarkers in amyotrophic lateral sclerosis.

Authors:  Ying Si; Xianqin Cui; Soojin Kim; Robert Wians; Robert Sorge; Shin J Oh; Thaddeus Kwan; Mohammad AlSharabati; Liang Lu; Gwen Claussen; Tina Anderson; Shaohua Yu; Dylan Morgan; Mohamed Kazamel; Peter H King
Journal:  Ann Clin Transl Neurol       Date:  2014-10-01       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.